Connor Tsuchida is a Scientific Co-Founder and the Vice President, Research & Development at Azalea Therapeutics, a biotechnology company pioneering in vivo genome editing therapies with cell and genomic precision. He earned his PhD in Bioengineering from UC Berkeley and UCSF, where he trained under Nobel Laureate Jennifer Doudna. His doctoral research focused on developing novel technologies to enhance the efficacy and safety of CRISPR-Cas genome editing in T cells -- work that was foundational to the founding of Azalea Therapeutics. Connor has been recognized by Forbes 30 under 30, the San Francisco Business Times 40 under 40, and the Seibel Scholarship for Bioengineers.